A Proof-of-concept Trial to EvaluAte the efficaCy and Safety Of Cell Therapy TRX103 in Patients With Active, Non-infectious Uveitis

Phase 1 Not yet recruiting 18 enrolled Quan Dong Nguyen

Non-randomizedSequentialOpen-labelTreatment

Summary

The purpose of this Phase 1, first in uveitis open-label study is to assess the safety and tolerability of TRX-103 in patients with non infectious uveitis (NIU). It is anticipated that up to 18 Subjects will be enrolled during a 18-24 month enrollment period. TRX-103 will be infused one time.

Timeline

Start: 2026-03
Primary completion: 2028-12
Completion: 2028-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	TRX103	Unknown	—	—

A Proof-of-concept Trial to EvaluAte the efficaCy and Safety Of Cell Therapy TRX103 in Patients With Active, Non-infectious Uveitis

Summary

Timeline

Drugs

Indications